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Phenylketonuria (PKU) is one of the most common inherited 
metabolic diseases, which is classified into classic and non-classic 
types. It is estimated that 2% of children with PKU develop a severe 
and progressive neurological disease, called non-classic (malignant) 
PKU. This study aimed to demonstrate the clinical features, laboratory 
findings, and diagnostic/therapeutic characteristics of non-classic 
PKU patients referred to a tertiary referral center for children in 
Tehran, Iran.
Materials & Methods
In this study, background information, such as gender and age, clinical 
manifestations, laboratory findings, and response rate to conventional 
treatment, was investigated in patients with non-classic PKU, who 
were referred to Mofid Children’s Hospital in Tehran, Iran, through 
neonatal screening. 
Results
Twenty patients with a diagnosis of non-classic PKU were included in 
this study. The mean age of the patients was 6.00±2.81 years (range: 
2-12 years), and 45.0% were male. In patients with a late diagnosis, 
the most common presentations were motor developmental delay 
(15.0%), skin and cutaneous manifestations (15.0%), seizure (5.0%), 
and restlessness (5.0%). The overall response rate to treatment was 
85.0%. Factors that predict good response to treatment included 
female gender, higher neopterin level, and lower age at diagnosis and 
management.
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Introduction
Inborn errors of metabolism are rare genetic 
disorders in which the body cannot turn food into 
energy. Although all of these disorders are rare, 
their number and diversity are high; therefore, 
they make up the most common group of genetic 
disorders. Untreated metabolic disorders, based 
on their pathophysiology, may result in severe 
presentations, such as mental retardation (1). 
Phenylketonuria (PKU) is one of the most common 
inherited metabolic diseases in the world, which 
is commonly classified as classic (phenylalanine 
hydroxylase [PAH] deficiency) and non-classic 
(severe and malignant tetrahydrobiopterin [BH4] 
deficiency) (2-4).
PAH deficiency is an inherited autosomal recessive 
defect in the metabolism of phenylalanine, causing 
a significant increase in phenylalanine to levels 
above 20 mg/dL (1200 µmol/L); this type of 
PAH deficiency is called classic PKU. A small 
percentage of patients have no PAH deficiency but 
lack BH4 synthesis and recycling as a cofactor of 
PAH. This leads to a defect in the biosynthesis of 
catecholamines and serotonin, resulting in a more 
serious neurological complication, called non-
classic (malignant) PKU (5).
Conclusion
In conclusion, about half of patients with non-classic PKU 
remain asymptomatic, which is due to early diagnosis 
via neonatal screening. Also, higher age at diagnosis and 
treatment, besides low neopterin levels, may be useful as 
prognostic factors.
Keywords: Phenylketonuria; Non-classic PKU; 
Hyperphenylalaninemia; Hypotonia; Neoptrin
DOI:10.22037/ijcn.v15i3.30519
Generally, inborn errors of metabolism comprise 
a heterogeneous group of disorders, caused by 
mutations in one of the genes encoding enzymes 
involved in biosynthesis (guanosine triphosphate 
cyclohydrolase [GTPCH] or 6-pyruvoyl-
tetrahydropterin synthase [PTPS]) or regeneration 
(pyruvate carboxylase deficiency [PCD] or 
dihydropteridine reductase [DHPR] of BH4. 
Hyperphenylalaninemia (HPA), which is present in 
the majority of patients, may be detected through 
neonatal PKU screening programs. Diagnosis 
of non-classic PKU among patients with HPA 
requires the measurement of pterins (neopterin 
and biopterin) in the urine, DHPR activity in the 
blood, and neurotransmitter metabolites in the 
cerebrospinal fluid (CSF).
The primary enzyme defect and its severity, the 
outcome of BH4 challenge, type of mutation, and 
response to therapy are some of the criteria used 
to define the prognosis of PKU. The terms severe/
generalized and mild/peripheral/partial should be 
used, according to the patient’s need for treatment 
with neurotransmitter precursors (5, 6). Use of 
older terms, such as atypical PKU (non-PKU 
HPA) or malignant PKU, should be avoided, as in 
most cases, a BH4 deficiency is no longer lethal 
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(6). Today, older children are detected based on 
different clinical symptoms, such as hypotonia 
of the trunk, hypertonia of the extremities, and 
often myoclonic seizures, unresponsive to a 
low-phenylalanine diet. Neonates with PKU are 
asymptomatic at the beginning of the disease and 
may not show relevant abnormalities within the 
first few months; therefore, a timely diagnosis can 
prevent these damaging processes (7).
Despite the high prevalence of PKU and the 
differences observed in the epidemiological and 
clinical aspects of this disease, studies on non-
classic PKU are limited. In this study, we aimed to 
evaluate the clinical features, laboratory findings, 
and diagnostic and therapeutic properties of non-
classic PKU patients, referred to a tertiary referral 
center for children in Tehran, Iran.
Materials & Methods
In this cross-sectional study, the clinical and 
laboratory information of patients with non-classic 
PKU was collected by reviewing their hospital 
records. Their background information, such as 
gender, age, clinical manifestations, laboratory 
findings, and response to conventional treatment, 
was also investigated. 
Descriptive analyses, including mean±standard 
deviation (SD) for quantitative variables and 
frequency (percentage) for comparative variables, 
were used to delineate the data. Chi-square test, 
t-test, or Mann-Whitney U test was used for 
comparison of variables. For statistical analysis, 
SPSS version 22.0 (released in 2013, IBM Corp., 
Armonk, NY, USA) was used. P-values less than 
0.05 were considered statistically significant. 
Patients with incomplete medical records or 
without follow-up were excluded from the study. 
Informed consent was obtained from all human 
adult participants and the parents or legal guardians 
of minors. The Research Ethics Committee of 
Shahid Beheshti University of Medical Sciences 
approved the study protocol. 
Results
Twenty patients with non-classic PKU were 
included in this study. The mean age of the patients 
was 6.00±2.81 years (range: 2-12 years), and 
45.0% were male. The baseline information of the 
patients is summarized in Table 1. A family history 
of PKU was only reported in 15.0% of the patients, 
while consanguinity was found in 70.0%. 
Overall, 30% of the patients in this study were 
diagnosed in the national screening program. In the 
remaining patients with a late diagnosis, the most 
common presentations were motor developmental 
delay (15.0%), skin and cutaneous manifestations 
(15.0%), seizure (5.0%), and restlessness (5.0%). 
None of the patients had organomegaly or 
cardiopulmonary abnormalities. The mean age 
at diagnosis was 37.06±31.67 months. The most 
common subtype was DHPR deficiency (45.0%), 
followed by PTPS deficiency (30.0%) and PCD 
(25.0%). 
An appropriate response to treatment was found in 
17 out of 20 patients, yielding an overall response 
rate of 85.0%. Positive response to treatment 
was significantly higher in females than in males 
(100% vs. 66.7%; P=0.038), and was independent 
of family history of PKU (P=0.998), parental 
consanguinity (P=0.521), and different subtypes of 
PKU (P=0.277). As shown in Table 2, the mean 
neopterin level was significantly lower in patients 
with treatment failure as compared to those who 
responded appropriately to treatment (2.10±0.52 
vs. 11.528.86±; P<0.001). However, response 
to treatment was not dependent on the level of 
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biopterin or phenylalanine. Besides, those with a 
higher chance of better response to treatment had 
a lower mean age at diagnosis and upon treatment 
(Table 2). Therefore, the main indicators for 
predicting a better treatment response were female 
gender, higher neopterin levels, and lower age at 
diagnosis and management. 
Based on the receiver operating characteristic 
(ROC) curve analysis, higher age (AUC=0.948), 
higher age at diagnosis (AUC=0.719), and neopterin 
deficiency (AUC=0.938) could effectively predict 
poor prognosis in non-classic PKU patients. The 
best cut-off values of variables for predicting 
better outcomes were 6.5 years for the patient’s 
age (sensitivity of 100% and specificity of 81.2%), 
36 months for age at diagnosis (sensitivity of 
100% and specificity of 56.2%), and 3.50 for the 
neopterin level (sensitivity of 87.5% and specificity 
of 100%) (Figure 1).
Table 1. Baseline characteristics of study population
Mean age, year 6.00 ± 2.81
Male gender 9 (45.0)
Mean weight, kg 2.65 ± 0.53
Mean height, cm 47.75 ± 3.02
Mean head circumference, cm 33.50 ± 1.97
Family history of PKU 3 (15.0)
Parents relative condition 14 (70.0)
Clinical manifestations
Restlessness 1 (5.0)
Skin problems 3 (15.0)
Motor delay 3 (15.0)
Thalassemia minor 2 (10.0)
Seizure 1 (5.0)
Mean age at diagnosis, month 37.06 ± 31.67
Mean level of neoptrin 10.53 ± 8.86
Mean level of bioptrin 2.31 ± 2.13
Mean level of phenyl alanine 9.83 ± 4.17
Types of non-classic PKU
 DHPR deficiency 6 (45.0)
PCD deficiency 5 (25.0)
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Table 2. Response rate according to baseline indicators
Item Response (+) Response (-) P value
Mean age 5.29 ± 2.23 10.00 ± 2.65 0.004
Mean weight 2.66 ± 0.56 2.60 ± 0.36 0.855
Mean height 48.24 ± 2.41 45.00 ± 5.19 0.394
Mean head circumference 33.54 ± 2.11 33.33 ± 1.16 0.875
Mean age at diagnosis 36.38 ± 32.56 64.00 ± 18.33 0.025
Mean level of neoptrin 11.52 ± 8.86 2.10 ± 0.52 0.001
Mean level of bioptrin 2.32 ± 2.45 2.31 ± 3.18 0.996
Mean level of phenyl alanine 8.76 ± 2.56 10.90 ± 5.79 0.218
Figure 1. The ROC curve analysis to predict successful PKU treatment based on the age at diagnosis, patient's age and the level of neoptrin
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Discussion
In the present study, the clinical features, 
laboratory findings, and response to treatment 
were investigated among non-classic PKU 
patients. Also, factors associated with a better 
prognosis were examined in these patients. In the 
current study, the effect of female and male gender 
was similar. Most of the patients had a negative 
family history of the disease, while consanguinity 
was found in 70% of the patients. The common 
clinical manifestations included motor delay, 
eczema, seizure, and restlessness; nevertheless, a 
significant proportion of patients (11 out of 20) 
were completely asymptomatic. Organomegaly 
was not detected in any of the patients; all of them 
showed normal cardiopulmonary responses. The 
average time from birth until diagnosis was about 
three years, which is a significant time interval. 
Besides, the response rate to treatment was 70% in 
our patients.
In this regard, poor prognosis has been reported in 
children with higher age at diagnosis, older age, 
and low neopterin levels; these factors predicted 
the treatment failure in the patients. Based on the 
epidemiological distribution of PKU in Iran, the 
results may differ from those reported in other 
parts of the country. In a study by Koochmeshgi 
et al., the parents were first cousins in 56% of 
cases (8). Moreover, in a study by Eshraghi et al. 
in Mazandaran, Iran, 70% of the patients were 
boys, and the mean age of diagnosis was 20 
months. Also, in their study, 60% of the patients 
had consanguineous parents, and 10% had a 
history of PKU in their siblings (9). Besides, 
Morovatdar et al. reported mental retardation in 
60% of patients and seizure in 36% of patients 
with PKU in Mashhad, Iran. In 80% of patients, 
consanguineous parents were reported, and 49% 
of the patients were male (10). Therefore, it can 
be concluded that the epidemiological distribution 
of PKU in different regions of the country is not 
completely homogeneous.
In a case-series of seven malignant PKU cases 
in Ireland, two patients had PTPS deficiency, 
and five patients showed DHPR deficiency. This 
finding is similar to our results, which revealed 
that DHPR deficiency (45.0%) was the most 
common subtype, followed by PTPS deficiency 
(30.0%) (11). Based on the evaluation of response 
to treatment and its dependence on indicators, such 
as age, age of diagnosis, and neopterin level, our 
findings are consistent with a study by Dayasiri 
et al., which reported a case of progressive 
neurological dysfunction secondary to malignant 
HPA, with a markedly reduced neopterin level and 
an undetectable biopterin level (12).
Some researchers have confirmed treatment failure 
in older patients or those with a late diagnosis. It is 
well-documented that diagnostic measures should 
be taken before the third week of life, and treatment 
must start before the first month of diagnosis (13). It 
has also been shown that the effect of treatment on 
intellectual status decreases with age. Therefore, to 
prevent the complications of the disease, the onset 
of treatment after 12 to 14 years will not exert 
significant effects on the patient’s mental status 
(14, 15). Based on the current guidelines, treatment 
should begin within the first ten days after birth; this 
will be only possible when diagnosis and treatment 
are done in the initial screening of the disease. 
Otherwise, with delayed diagnosis and treatment, 
irreversible complications, such as delayed disease 
development, recurrent seizures, and significant 
mental retardation, may occur. According to our 
findings, factors, such as age at diagnosis >3 years 
and a neopterin level <3.50 can be considered as 
137
Clinical and Paraclinical Characteristics of Non-Classic Phenylketonuria
Iran J Child Neurol. Summer 2021 Vol. 15 No. 3
helpful clinical criteria for a poor prognosis.
In the present study, there were some potential 
limitations. First, because of the rarity of PKU, we 
had a small sample size, which made it impossible 
to evaluate and remove the confounding factors for 
determining the predictors of prognosis. Second, it 
was not possible to evaluate the genetic variations 
in different PKU subgroups. Third, due to the cross-
sectional design of this study, it was not possible 
to investigate the patients’ response to long-term 
treatment or their long-term survival.
In Conclusion
According to the findings of this study, lower age 
at diagnosis and treatment and a high neopterin 
level are useful prognostic factors in non-classic 
PKU.
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